PH Center Research Participation
Currently, the PH Center is participating in two industry sponsored trials:
AMBITION: Patients with Pulmonary Arterial Hypertension and mild to moderate symptoms are placed on either ambrisentan (Letairis) or tadalafil (Adcirca) or a combination of the two. The goal is to determine whether there is a benefit to combination therapy.
PROSPECT: Patients receiving room temperature stable epoprostenol (Veletri) are monitored over time to determine long term efficacy and dosing schemes for these drugs.
Locally, all patients who undergo Right Heart Catheterization for the diagnosis of Pulmonary Hypertension are asked to enroll in the PH Registry, an anonymous database that we use to identify trends and develop future research projects. We are also investigating levels of chemicals (called micro-RNAs) in the blood of patients with PH to hopefully improve diagnosis and treatment in the future.